RSS

Staphylococcus aureus (S. aureus)

Clinical stage biotechnology company, Destiny Pharma, has announced that the US Food and Drug Administration (FDA) has accepted its investigational new drug application (IND) for its lead clinical drug candidate, XF-73. more

News

Motif Bio’s investigational drug candidate, iclaprim, has been granted orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of Staphylococcus aureus lung infections in patients with cystic fibrosis. more

News

Cepheid is collaborating with Combacte and MedImmune, to identify pneumonia bacteria in patients so they can be entered into clinical programmes more

News